Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Authors

Levent Mutlu, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Blair McNamara, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Stefania Bellone, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT.
Diego D. Manavella, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Cem Demirkiran, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Michelle Greenman, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Migues Skyler Z. Veroza, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Natalia Buza, Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
Pei Hui, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Tobias Max Philipp Harwitch, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Justin Harold, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Margherita Zipponi, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Gary Altwerger, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, CT, 06510, USA.
Elena Ratner, Department of Obstetrics, Gynecology, and Reproductive Sciences, 333 Cedar Street, LSOG 305, PO Box 208063, New Haven, CT, 06520, USA.
Gloria S. Huang, Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Mitchell Clark, Department of Obstetrics/Gynecology, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT.
Vaagn Andikyan, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA.
M Azodi, Yale University, New Haven, Connecticut.
Peter E. Schwartz, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Alessandro D. Santin, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT.

Document Type

Article

Publication Title

Clinical and Experimental Metastasis

First Page

765

Last Page

778

DOI

10.1007/s10585-024-10297-z

Publication Date

10-2025

Recommended Citation

Mutlu L, McNamara B, Bellone S, Manavella DD, Demirkiran C, Greenman M, Verzosa MSZ, Buza N, Hui P, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Santin AD. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clin Exp Metastasis. 2024 Oct;41(5):765-775. doi: 10.1007/s10585-024-10297-z.

Source Document Type

English

e-ISSN

1573-7276